Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against UniQure N.V. due to allegations of violations of federal securities laws, particularly concerning misleading statements related to the company's Pivotal Study and its implications for the BLA submission timeline [4][6]. Group 1: Allegations Against UniQure - The complaint alleges that UniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design [6]. - It is claimed that the company downplayed the likelihood of needing to delay its BLA submission due to additional studies [6]. - The statements made by the defendants about the company's business and prospects are said to lack a reasonable basis [6]. Group 2: Impact of FDA Disclosure - On November 3, 2025, UniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous representations [7]. - Following this disclosure, UniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [8]. Group 3: Legal Proceedings - Investors who suffered losses in UniQure are encouraged to contact Faruqi & Faruqi to discuss their legal options, with a deadline of April 13, 2026, to seek the role of lead plaintiff in the class action [4][9]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. Group 4: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding UniQure's conduct [10].

Core Viewpoint - Hagens Berman is updating its investigation into uniQure N.V. following significant criticisms from the FDA regarding the company's gene therapy candidate AMT-130, which has been labeled a "failed therapy" by FDA officials [2][3]. Group 1: FDA Allegations - The FDA has accused uniQure of conducting a "distorted or manipulated comparison" in its clinical studies, suggesting that the company did not run a proper clinical study [2][4]. - Allegations include that uniQure misrepresented its interactions with the FDA and used a pivotal study design that was not approved by the agency [3][4]. Group 2: Class Action Details - A securities class action lawsuit has been filed against uniQure, alleging that the company failed to disclose critical information regarding the eligibility of AMT-130 for the "Plausible Mechanism" pathway and mischaracterized the requirements for sham surgeries [4][5]. - The lawsuit claims that uniQure misled investors about the timing of a Biologics License Application (BLA), which became unclear after the FDA's lack of agreement was revealed, resulting in a 49% drop in stock price [5][6]. Group 3: Critical Deadlines - Investors who purchased uniQure shares during the class period from September 24, 2025, to October 31, 2025, have until April 13, 2026, to apply as Lead Plaintiff in the ongoing securities class action [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 13, 2026, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the design of its Pivotal Study for a drug candidate related to Huntington's Disease, which was not fully approved by the FDA [4] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [4] - The lawsuit asserts that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [4]

Core Points - Holzer & Holzer, LLC is reminding investors about the deadline to seek lead plaintiff status in class action lawsuits against Kyndryl Holdings, Inc. and uniQure N.V. [1][2] - The lawsuit against Kyndryl alleges that the company made materially false and misleading statements regarding its financial statements from August 7, 2024, to February 9, 2026 [1] - The lawsuit against uniQure claims that the company failed to disclose material facts about the design of its Pivotal Study between September 24, 2025, and October 31, 2025 [2] Company Information - Holzer & Holzer, LLC is recognized as an ISS top-rated securities litigation law firm for the years 2021, 2022, 2023, and 2025, focusing on shareholder and investor representation in litigation [3] - The firm has been involved in recovering hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct since its establishment in 2000 [3]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging misrepresentations regarding the drug AMT-130, which was being developed for Huntington's Disease [1][5]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements about AMT-130, impacting the company's stock value [5]. - Investors who acquired uniQure shares during the specified period may be eligible to join the class action [2][3]. - The deadline to file as a lead plaintiff is April 13, 2026, and participation does not require serving as a lead plaintiff [4]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [6]. - All representation in this lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses unless there is a recovery [4].

Core Viewpoint - uniQure N.V. is facing a securities class action lawsuit due to alleged misleading statements regarding the clinical trial design of its lead gene therapy candidate, AMT-130, particularly concerning the FDA's acceptance of a pivotal study design that lacked a traditional placebo control [2][4]. Group 1: Lawsuit Details - The lawsuit claims that uniQure and its executives made inaccurate statements about the regulatory path for AMT-130, which is intended to treat Huntington's disease [3][4]. - The class period for the lawsuit is from September 24, 2025, to October 31, 2025, with a lead plaintiff deadline set for April 13, 2026 [3]. - The complaint alleges that the truth about the FDA's stance was revealed on November 3, 2025, when uniQure stated that the FDA no longer agreed that the data from the Phase I/II studies were adequate for a Biologics License Application (BLA) submission [4]. Group 2: Financial Impact - Following the disclosure regarding the FDA's position, uniQure's stock price fell by more than 49% [4]. - The firm Hagens Berman is investigating claims that uniQure violated federal securities laws and is urging investors who suffered significant losses to come forward [3][5]. Group 3: Regulatory Concerns - The investigation focuses on the discrepancies between what uniQure communicated to investors about its interactions with the FDA and the details revealed in the Type A meeting minutes [5]. - Defendants allegedly downplayed the likelihood of needing to delay the BLA timeline to conduct additional studies, despite previously reported successful results from the AMT-130 pivotal study [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including the lack of full FDA approval for the study design [5]. - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies, which affected the credibility of the company's statements about its business and prospects [5]. - The lawsuit asserts that when the true details became public, investors suffered damages as a result of these misrepresentations [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and recovering over $438 million for investors in 2019 alone [4].

Core Viewpoint - Federal health officials have publicly condemned uniQure N.V. for allegedly providing misleading information regarding its gene therapy candidate AMT-130, which is intended to treat Huntington's disease, leading to a significant decline in the company's stock price and the initiation of a securities class action lawsuit [3][4][5]. Company Overview - uniQure N.V. is under investigation by Hagens Berman following a class action lawsuit that targets investors who acquired shares between September 24, 2025, and October 31, 2025 [1][6]. - The company's lead gene therapy candidate, AMT-130, has faced scrutiny from the FDA, which stated that the data from its testing was flawed and did not meet the approval criteria [4][5]. Allegations and Legal Proceedings - The class action lawsuit alleges that uniQure misrepresented the adequacy of data from its Phase I/II studies and failed to disclose that the FDA did not approve the design of its pivotal study [6][7]. - The lawsuit claims that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the need for additional studies [7]. - Following the negative reports, uniQure's stock price plummeted nearly 84% from November 3, 2025, to the time of the Wall Street Journal publication [5]. Financial Impact - The announcement regarding the unclear timing of the BLA submission for AMT-130 resulted in a more than 49% drop in uniQure's share price [8]. - The investigation by Hagens Berman focuses on discrepancies between what uniQure communicated to investors and the details revealed in recent FDA meeting minutes [9].

Core Viewpoint - The article discusses a securities class action against uniQure N.V. (NASDAQ: QURE) due to allegations of misleading statements and failure to disclose critical information regarding the company's Pivotal Study and its implications for the BLA submission timeline [1][2]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives violated federal securities laws by making false and/or misleading statements [1]. - Specific allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its BLA timeline for additional studies [1]. - The complaint asserts that the statements made by the defendants regarding the company's business, operations, and prospects lacked a reasonable basis [1]. Group 2: Impact of FDA Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would be adequate to support a BLA submission [1]. - The company admitted that the timing of any BLA submission for AMT-130 was now unclear, contradicting previous representations of a near-term path toward accelerated approval [1]. - Following this disclosure, uniQure's share price fell by $33.40, or more than 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1]. Group 3: Class Action Participation - The article outlines that the court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class [1]. - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [1]. - The law firm Faruqi & Faruqi, LLP encourages anyone with information regarding uniQure's conduct to contact them, including whistleblowers and former employees [2].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified Class Period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [2]. Allegations - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130 and downplayed the potential need to delay its Biologics License Application (BLA) timeline due to additional studies [3]. Stock Impact - Following the disclosure on November 3, 2025, that the FDA did not accept the Phase I/II data as primary evidence for a BLA submission, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share on November 3, 2025 [4].